Log inSign up
Pharma-Marketing.comPharma-Marketing.com
  • Industry
  • Digital Health & AI
  • Channels
  • People
  • Agencies
  • Glossary
Log inSign up
  • Terms of Service
  • Privacy Policy
  • Cookie settings
  • Imprint
Pharma-Marketing.com


All rights reserved.

We use AI tools in the creation of certain content.

Pharma Marketing

Data-privacy settings

We use cookies to improve our website and services. They help us understand how visitors use our website. Some cookies are required for the website to function. These are marked as “essential” in the details.

AcceptEssential cookie
NameData-privacy settings
ProviderPharma-Marketing.com
PurposeStores these privacy settings in your browser.
Privacy policyPrivacy policy
Cookiespm_data_privacy
Cookie expiration180 days
Accept
NameGoogle Analytics
ProviderGoogle LLC
PurposeCookies by Google are used for website analytics. Generates statistical data on how the visitor uses the website.
Privacy policyPrivacy policy
Cookies_ga, _gat, _gid
Cookie expiration2 Years
Accept
NameGoogle Ads
ProviderGoogle LLC
PurposeCookies by Google Ads are used for advertising and targeting purpose.
Privacy policyPrivacy policy
Cookies__gsas, __gpi, __gpi_optout, NID, DSID, test_cookie, id, __gads
Cookie expiration2 Years
Accept
NameFacebook
ProviderFacebook Inc.
PurposeCookies by Facebook are used for advertising and marketing activities. Generates statistical data on how the visitor uses the website.
Privacy policyPrivacy policy
Cookies_fbp, fr
Cookie expiration2 Years
Accept
NameMicrosoft Clarity
ProviderMicrosoft Corporation
PurposeCookies by Microsoft Clarity are used for website analytics, heatmaps, and session recordings. They help us understand how visitors interact with our website so we can improve usability and performance.
Privacy policyPrivacy policy
Cookies_clck, _clsk, CLID, ANONCHK, MR, MUID, SM
Cookie expirationUp to 1 Year
© Image modified: Biomarin

Thursday, August 20, 2026

BioMarin to acquire Alesta for HPP candidate ALE1

BioMarin Pharmaceutical has agreed to acquire Alesta Therapeutics to obtain ALE1, a clinical-stage candidate for hypophosphatasia. The deal includes an upfront payment of $275 million and potential additional payments of up to $215 million tied to development and regulatory milestones.

The transaction has been approved by both companies’ boards. BioMarin expects closing to take place this quarter, subject to customary conditions, and plans to use cash on hand to fund the acquisition.

Oral small molecule for a rare bone disorder

ALE1 is an orally active small molecule being developed for hypophosphatasia, or HPP. The rare genetic bone disease is caused by mutations in the ALPL gene and can impair mineralization of bone and teeth. Symptoms may include frequent fractures, early tooth loss and, in adults, muscle weakness, fatigue and pain.

The asset is currently being evaluated in a Phase 1/2a trial that is assessing safety, tolerability, pharmacokinetics and pharmacodynamics in healthy volunteers and adults with HPP. If approved, ALE1 could become the first oral treatment approach for the condition, according to BioMarin.

Strategic fit for BioMarin’s pipeline

BioMarin positions the program as an addition to its early clinical pipeline and as a potential entry into a larger rare disease opportunity. After closing, ALE1 is expected to become part of the company’s Skeletal Conditions Business Unit.

Before completion of the acquisition, Alesta plans to separate all assets not related to ALE1 into a new company. Alesta employees are also expected to move to that spinout, meaning no Alesta staff will join BioMarin as part of the transaction.

Financial and advisory details

BioMarin said it will update its full-year 2026 guidance after the deal closes. Excluding the upfront consideration, the company expects a modestly dilutive effect on 2026 financial results.

Morgan Stanley is serving as exclusive financial adviser to BioMarin, with Jones Day as legal counsel. J.P. Morgan Securities is advising Alesta exclusively on financial matters, while Goodwin Procter and NautaDutilh are providing legal advice.

Advertisement

Only a few physicians log in to your website?

Advertisement

A login that sets a new standard for authenticating HCPs and equips your marketing team with everything they need to successfully promote Rx-products. Learn more on DocID.pro


Stay up to date!

Subscribe to our free Pharma-Marketing-Newsletter.


A Partner For Successful Marketing in Pharma & Healthcare

Advertisement

8awake, the specialized agency for pharma and healthcare marketing, supports you with the successful development and execution of winning campaign activities in healthcare.

Leading providers in pharma and healthcare marketing

Sponsored
  • MINTT Digital
  • 8awake
  • MINTT Digital

  • 8awake

    The leading Healthcare & Pharma-Marketing-Agency

Looking for a new partner in pharma and healthcare marketing?

Visit our agency finder

Copyright 2026 Pharma-Marketing.com.